Deficiency

AMGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Lawsuit

Retrieved on: 
Monday, March 20, 2023
Pension fund, AMGN, CASE, ASC, IRS, Tax, Government, Complaint, Deficiency, Risk, SAN, News, Tobacco, Cryptocurrency, Amgen

), the Amgen class action lawsuit charges Amgen as well as certain of Amgen’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Amgen class action lawsuit charges Amgen as well as certain of Amgen’s top executives with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Amgen class action lawsuit must be filed with the court no later than May 12, 2023.
  • The lead plaintiff can select a law firm of its choice to litigate the Amgen class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Amgen class action lawsuit.

AMGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Files Securities Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Lawsuit

Retrieved on: 
Saturday, March 18, 2023
Class Action Lawsuit, Professional Services, Legal, Pension fund, AMGN, CASE, ASC, IRS, Tax, Government, Complaint, Deficiency, Risk, News, Tobacco, Cryptocurrency, Amgen

), the Amgen class action lawsuit charges Amgen and certain of Amgen’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Amgen class action lawsuit charges Amgen and certain of Amgen’s top executives with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Amgen class action lawsuit must be filed with the court no later than May 12, 2023.
  • The lead plaintiff can select a law firm of its choice to litigate the Amgen class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Amgen class action lawsuit.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Match, Credit Suisse, SVB, and Amgen and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 18, 2023
AMGN, MTCH, Reuters, Tax, OkCupid, Credit Suisse, SVB, Investment, Financial Times, Risk, Environment, News, NYSE, Bloomberg Television, SIVB, Defendant, P.C, ASC, IRS, Interview, Risk management, Growth, Credit, Social media, Match Group, Shareholder, POF (dating website), Government, Deficiency, Complaint, Tinder, ADS, Swiss Financial Market Supervisory Authority, CS, Silicon, Holding company, Cryptocurrency, Audit, Lithium, Amgen, Match

Tinder, which generated more than half of Match’s revenue during the Class Period, is Match’s largest and most important brand.

Key Points: 
  • Tinder, which generated more than half of Match’s revenue during the Class Period, is Match’s largest and most important brand.
  • In a letter to shareholders, Defendants touted Tinder’s “radical product transformation,” which included recently launched product initiatives such as a new “Explore” feature.
  • For more information on the SVB class action go to: https://bespc.com/cases/SIVB
    Amgen is one of the world’s largest independent biopharmaceutical companies.
  • On this news, the price of Amgen common stock fell by an additional 4.3%, further damaging investors.

AMGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, March 15, 2023
Class Action Lawsuit, Professional Services, Legal, Electric Bond and Share Company v. Securities and Exchange Commission, ASC, Person, Risk, Telephone, Deficiency, AMGN, Jeanne Eagels, District court, Government, Court, IRS, Tax, P.C, News, Cryptocurrency, Life insurance, Amgen

Investors have until May 15, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 15, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Amgen is one of the world’s largest independent biopharmaceutical companies.
  • On this news, the price of Amgen common stock fell by an additional 4.3%, further damaging investors.

AMGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

Retrieved on: 
Tuesday, March 14, 2023
Class Action Lawsuit, Professional Services, Legal, AMGN, ASC, CASE, Complaint, Pension fund, Tax, Risk, Deficiency, News, IRS, Government, Tobacco, Cryptocurrency, Amgen

), the Amgen class action lawsuit charges Amgen and certain of Amgen’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Amgen class action lawsuit charges Amgen and certain of Amgen’s top executives with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Amgen class action lawsuit must be filed with the court no later than May 12, 2023.
  • The lead plaintiff can select a law firm of its choice to litigate the Amgen class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Amgen class action lawsuit.

Nasdaq Approves 180-Day Extension for Mullen Automotive to Meet Minimum $1 Bid Price

Retrieved on: 
Wednesday, March 8, 2023
Calendar, Mullen Technologies, Deficiency, Auction

BREA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Mullen Automotive, Inc. (NASDAQ: MULN ) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that Nasdaq has approved the Company’s request for a 180-day extension to meet the $1 minimum bid price requirement.

Key Points: 
  • BREA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Mullen Automotive, Inc. (NASDAQ: MULN ) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that Nasdaq has approved the Company’s request for a 180-day extension to meet the $1 minimum bid price requirement.
  • On Sept. 7, 2022, Nasdaq provided notice to the Company that, based on the previous 30 consecutive business days, the Company’s listed common stock no longer met the minimum $1 bid price per share requirement as set forth in Nasdaq Listing Rule 5810(c)(3)(A)(ii) (the “Deficiency”).
  • The Company was provided 180 calendar days, or until March 6, 2023, to regain compliance.
  • “Consistent with my message to our shareholders, we will use our best efforts to regain compliance to meet Nasdaq’s requirement for a $1 minimum bid price," said David Michery, CEO and chairman of Mullen Automotive.

AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)

Retrieved on: 
Tuesday, December 13, 2022
Euronext Paris, Cell, AMF, NOD, Medicine, Inflammation, Science, Marketing, Degenerative disease, Pengkhianatan G30S/PKI, Calendar, Amyotrophic lateral sclerosis, Tyrosine kinase inhibitor, Survival, AB, Research, NON, Euronext, Veterinary medicine, Health Canada, Pharmaceutical industry, Publishing, Deficiency

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis.

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis.
  • This NOD means that Health Canada has requested the provision of additional information related to masitinib New Drug Submission.
  • The Response to a Notice of Deficiency is to be submitted within 90 calendar days from the date the NOD was sent.
  • AB Science will liaise with Health Canada to address the deficiencies, with the intention to resume the process within the allocated timeframe.

Galactosemia Drug Pipeline Market Report 2022 Featuring Applied Therapeutics, Jaguar Gene Therapy, & BridgeBio Pharma - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Health, Pharmaceutical, FDA, Route of administration, NDA, CNS, Technology, Clinical trial, Route, Inflammatory demyelinating diseases of the central nervous system, Central nervous system, Birth, Lists of diseases, ARI, Jaguar, Degenerative disease, Discovery, Administration, Acquisition, Therapy, GALT, News, Deficiency, Medical device, Oil, Pharmaceutical industry, Glycosylation, Galactosemia

This Galactosemia- Pipeline Insight, 2022 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Galactosemia pipeline landscape.

Key Points: 
  • This Galactosemia- Pipeline Insight, 2022 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Galactosemia pipeline landscape.
  • "Galactosemia- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Galactosemia pipeline landscape is provided which includes the disease overview and Galactosemia treatment guidelines.
  • Galactosemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Retrieved on: 
Tuesday, July 19, 2022
Private Securities Litigation Reform Act, ABCC6, Corporation, Skin, GLOBE, DSMB, Blood, Deficiency, Investor relations, U.S. Securities and Exchange Commission, Skeleton, Lists of diseases, PD, Biomarker, Risk, ENPP1, Pseudoxanthoma elasticum, Adult, Safety, News, ADAS, Gene, Master of Science, Disorder, Clinical trial, Plasma, Pyrophosphate, AE, Ophthalmology, Technology, MBA, FDA, Company, Security (finance), Nasdaq, Pharmacokinetics, Doctor of Philosophy, Therapy, Annual report, Yale University, Șaeș, Calcification, PXE, Infant, Enzyme replacement therapy, Pharmaceutical industry, Management

BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects treated in the Phase 1 portion of its ongoing Phase 1/2 clinical trial of INZ-701 in adult subjects with ABCC6 Deficiency, which presents as pseudoxanthoma elasticum (PXE) in older individuals. At the 0.2 mg/kg dose level of INZ-701, all three subjects showed rapid and significant increases in PPi levels. In preclinical models, PPi was shown to be a key predictive biomarker of therapeutic benefit in ABCC6 Deficiency.

Key Points: 
  • Preliminary PK and INZ-701 enzymatic activity remained consistent with data previously reported from the Companys ongoing Phase 1/2 trial of INZ-701 in subjects with ENPP1 Deficiency.
  • The Company plans to report topline data from the ongoing Phase 1/2 clinical trial in ABCC6 Deficiency in the first quarter of 2023.
  • INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.
  • INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Retrieved on: 
Monday, April 4, 2022
Company, Exercise, Blood, Rickets, Data monitoring committee, Deficiency, CLIA, ECTS, Therapy, Private Securities Litigation Reform Act, Clinical trial, PK, Pharmacokinetics, Adult, Hearing loss, Clinical Laboratory, ABCC6, Myocardial infarction, Pyrophosphate, Half-life, PD, U.S. Securities and Exchange Commission, Generalized arterial calcification of infancy, LDT, Week, Skeleton, Safety, Review, Stroke, Technology, Calcification, Master of Science, Nasdaq, MBA, GLOBE, Gene, Osteomalacia, DSMB, Yale University, Meal, Lists of diseases, FDA, Annual report, ENPP1, Patient, Security (finance), Pharmaceutical industry, Dietary supplement

BOSTON, April 04, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced positive preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its ongoing first-in-human Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency. At the 0.2 mg/kg dose level of INZ-701, all three patients showed rapid, significant, and sustained increases in PPi levels. Preclinical findings demonstrated PPi as a key predictive biomarker of therapeutic benefit in ENPP1 Deficiency.

Key Points: 
  • We look forward to additional data from patients at the next dose levels in our ongoing clinical trial.
  • All three patients from the first cohort enrolled in the open-label Phase 2 48-week extension portion of the trial.
  • Following conclusion of the 32-day dose evaluation period, an independent Data Safety Monitoring Board (DSMB) reviewed preliminary data from the ongoing trial.
  • The ongoing Phase 1/2 open-label clinical trial is expected to enroll up to nine adult patients with ENPP1 Deficiency at sites in North America and Europe.